Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cevipabulin (TTI-237) is a microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin (IC50: 18-40 nM in the human tumor cell line).
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 11,500 | |||
5 mg | 在庫あり | ¥ 21,000 | |||
10 mg | 在庫あり | ¥ 32,000 | |||
25 mg | 在庫あり | ¥ 68,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 24,500 |
説明 | Cevipabulin (TTI-237) is a microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin (IC50: 18-40 nM in the human tumor cell line). |
ターゲット&IC50 | Microtubule (human tumor cells):18-40 nM |
In vitro | Cevipabulin (0-50 nM, 72 hours) shows good activity (IC50s: 18~40 nM) on cell lines from ovarian, breast, prostate, and cervical tumors. Cevipabulin at low concentrations (20-40 nM) produces sub-G1 nuclei and, at concentrations above 50 nM, it causes a strong G2-M block [1]. |
In vivo | In mice, Cevipabulin ( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles; i.v. and p.o.) is active against human tumor xenografts and showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg [1]. |
別名 | TTI-237 |
分子量 | 464.82 |
分子式 | C18H18ClF5N6O |
CAS No. | 849550-05-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 15.3 mg/mL (32.9 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cevipabulin 849550-05-6 Cytoskeletal Signaling Microtubule Associated TTI 237 TTI-237 TTI237 Inhibitor inhibitor inhibit